Literature DB >> 33498239

Inclusion Compound of Efavirenz and γ-Cyclodextrin: Solid State Studies and Effect on Solubility.

Susana Santos Braga1, Firas El-Saleh2, Karyna Lysenko1,3, Filipe A Almeida Paz3.   

Abstract

Efavirenz is an antiretroviral drug of widespread use in the management of infections with human immunodeficiency virus type 1 (HIV-1). Efavirenz is also used in paediatrics, but due to its very poor aqueous solubility the liquid formulations available resort to oil-based excipients. In this report we describe the interaction of γ-cyclodextrin with efavirenz in solution and in the solid state. In aqueous solution, the preferential host-guest stoichiometry was determined by the continuous variation method using 1H NMR, which indicated a 3:2 host-to-guest proportion. Following, the solid inclusion compound was prepared at different stoichiometries by co-dissolution and freeze-drying. Solid-state characterisation of the products using FT-IR, 13C{1H} CP-MAS NMR, thermogravimetry, and X-ray powder diffraction has confirmed that the 3:2 stoichiometry is the adequate starting condition to isolate a solid inclusion compound in the pure form. The effect of γ-cyclodextrin on the solubility of efavirenz is studied by the isotherm method.

Entities:  

Keywords:  antiretroviral; cyclodextrin inclusion; solid state; solution-phase

Year:  2021        PMID: 33498239      PMCID: PMC7863942          DOI: 10.3390/molecules26030519

Source DB:  PubMed          Journal:  Molecules        ISSN: 1420-3049            Impact factor:   4.411


  18 in total

1.  Solution and Solid State Nuclear Magnetic Resonance Spectroscopic Characterization of Efavirenz.

Authors:  Eduardo Gomes Rodrigues de Sousa; Erika Martins de Carvalho; Rosane Aguiar da Silva San Gil; Tereza Cristina Dos Santos; Leandro Bandeira Borré; Osvaldo Andrade Santos-Filho; Javier Ellena
Journal:  J Pharm Sci       Date:  2016-01-22       Impact factor: 3.534

2.  Synergistic encapsulation of the anti-HIV agent efavirenz within mixed poloxamine/poloxamer polymeric micelles.

Authors:  Diego A Chiappetta; Graciela Facorro; Emilio Rubin de Celis; Alejandro Sosnik
Journal:  Nanomedicine       Date:  2011-03-01       Impact factor: 5.307

Review 3.  Biowaiver monographs for immediate release solid oral dosage forms: efavirenz.

Authors:  Rodrigo Cristofoletti; Anita Nair; Bertil Abrahamsson; D W Groot; Sabine Kopp; Peter Langguth; James E Polli; Vinod P Shah; Jennifer B Dressman
Journal:  J Pharm Sci       Date:  2012-11-22       Impact factor: 3.534

4.  Efavirenz loaded nanostructured lipid carrier engineered for brain targeting through intranasal route: In-vivo pharmacokinetic and toxicity study.

Authors:  Varsha Pokharkar; Arpana Patil-Gadhe; Prathyusha Palla
Journal:  Biomed Pharmacother       Date:  2017-07-28       Impact factor: 6.529

5.  Impact of superdisintegrants on efavirenz release from tablet formulations.

Authors:  Yelchuri Vijaya Rajesh; Jagdish Balasubramaniam; Koduri Bindu; Ramachandran Sridevi; Maroju Swetha; Vinay Umesh Rao
Journal:  Acta Pharm       Date:  2010-06       Impact factor: 2.230

6.  Physicochemical characterization of efavirenz-cyclodextrin inclusion complexes.

Authors:  Sateeshkumar Sathigari; Gurkishan Chadha; Y-H Phillip Lee; Nydeia Wright; Daniel L Parsons; Vijay K Rangari; Oladiran Fasina; R Jayachandra Babu
Journal:  AAPS PharmSciTech       Date:  2009-01-16       Impact factor: 3.246

7.  Enhanced oral bioavailability of the antiretroviral efavirenz encapsulated in poly(epsilon-caprolactone) nanoparticles by a spray-drying method.

Authors:  Lesego Tshweu; Lebogang Katata; Lonji Kalombo; Diego A Chiappetta; Christian Hocht; Alejandro Sosnik; Hulda Swai
Journal:  Nanomedicine (Lond)       Date:  2013-12-23       Impact factor: 5.307

Review 8.  Efavirenz--still first-line king?

Authors:  Brookie M Best; Miguel Goicoechea
Journal:  Expert Opin Drug Metab Toxicol       Date:  2008-07       Impact factor: 4.481

9.  Inclusion of the Phytoalexin trans-Resveratrol in Native Cyclodextrins: A Thermal, Spectroscopic, and X-Ray Structural Study.

Authors:  Laura Catenacci; Milena Sorrenti; Maria Cristina Bonferoni; Lee Hunt; Mino R Caira
Journal:  Molecules       Date:  2020-02-24       Impact factor: 4.411

Review 10.  Cyclodextrins: Emerging Medicines of the New Millennium.

Authors:  Susana Santos Braga
Journal:  Biomolecules       Date:  2019-11-28
View more
  4 in total

1.  Characterization of the Inclusion Complexes of Isothiocyanates with γ-Cyclodextrin for Improvement of Antibacterial Activities against Staphylococcus aureus.

Authors:  Jianan Liu; Hongyan Wu; Xinying Ao; Hongshun Hao; Jingran Bi; Hongman Hou; Gongliang Zhang
Journal:  Foods       Date:  2021-12-27

2.  Enhanced oral bioavailability of koumine by complexation with hydroxypropyl-β-cyclodextrin: preparation, optimization, ex vivo and in vivo characterization.

Authors:  Qing Hu; Xiaoling Fu; Yanping Su; Yanfang Wang; Sihuan Gao; Xiaoqin Wang; Ying Xu; Changxi Yu
Journal:  Drug Deliv       Date:  2021-12       Impact factor: 6.419

3.  Risperidone/Randomly Methylated β-Cyclodextrin Inclusion Complex-Compatibility Study with Pharmaceutical Excipients.

Authors:  Laura Sbârcea; Ionuț-Mihai Tănase; Adriana Ledeți; Denisa Cîrcioban; Gabriela Vlase; Paul Barvinschi; Marinela Miclău; Renata-Maria Văruţ; Oana Suciu; Ionuț Ledeți
Journal:  Molecules       Date:  2021-03-17       Impact factor: 4.411

Review 4.  Cyclodextrins in Antiviral Therapeutics and Vaccines.

Authors:  Susana Santos Braga; Jéssica S Barbosa; Nádia E Santos; Firas El-Saleh; Filipe A Almeida Paz
Journal:  Pharmaceutics       Date:  2021-03-19       Impact factor: 6.321

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.